Lintuzumab-Ac225 vs PRGN-3006
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Acute Myeloid Leukemia
Shared mechanism: CD33 · full Acute Myeloid Leukemia pipeline
Lintuzumab-Ac225
Developed by Actinium Pharmaceuticals
NCT02575963 · Phase 1/2 · completed
The study enrolled 40 participants without randomization, blinding, or a comparator arm, so outcomes cannot be directly attributed to Lintuzumab-Ac225 relative to another treatment. Its primary remission result is not available because no results have been posted.
No aligned efficacy figure on record for this race.
PRGN-3006
Developed by Precigen, Inc
NCT03927261 · Phase 1 · active, not recruiting
This trial enrolled all participants into a single treatment group with no randomization, no blinding, and no comparator arm, which is typical of an early Phase 1 safety study. Its primary goal was to check for dose-limiting toxicities rather than to statistically compare efficacy against a control, and an outside report notes no DLTs were seen, but because there was never a control group there is no formal test of a treatment effect to point to.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Reported efficacy
Number of Participants who Experience Dose Limiting Toxicities (DLTs) (Up to Day 42); Number of Participants who Experience Treatment Emergent Adverse Events (TEAEs) (Up to 12 months post treatment): PRGN-3006 (NCT03927261): no dose-limiting toxicities (DLTs) observed. (not_applicable)
Result source: NCT03927261
Results for Acute Myeloid Leukemia
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Lintuzumab-Ac225 | PRGN-3006 |
|---|---|---|
| OS, median | —Not reported | —Not reported |
| Complete remission | —Not reported | —Not reported |
| Event-free survival, median | —Not reported | —Not reported |
| Duration of response, median | —Not reported | —Not reported |
OS, median
- Lintuzumab-Ac225
- —Not reported
- PRGN-3006
- —Not reported
Complete remission
- Lintuzumab-Ac225
- —Not reported
- PRGN-3006
- —Not reported
Event-free survival, median
- Lintuzumab-Ac225
- —Not reported
- PRGN-3006
- —Not reported
Duration of response, median
- Lintuzumab-Ac225
- —Not reported
- PRGN-3006
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Lintuzumab-Ac225: no structured comparison results are available for Acute Myeloid Leukemia.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Lintuzumab-Ac225's landscape · PRGN-3006's landscape